Are you using non-human cell models for your cardiac research? Download our new white paper to find out why switching to human iPSC-derived models could improve your data

    The rapid development of induced pluripotent stem cell-derived cells (iPSC) is set to revolutionise modern drug discovery through the increased utilisation of human cell reagents in research.

    The academic world is currently experiencing challenges as research into new therapies is progressing from traditional in vitro screening assays to preclinical ex vivo and in vivo animal models —and eventually into human clinical trials— with a lack of human translation that threatens the application of research.

    In this white paper we share the latest data, generated in collaboration with Metrion Biosciences, on cell models for human iPSC-derived atrial cardiomyocytes, and demonstrate how their implementation for research into diseases such as atrial fibrillation is allowing for the development of more effective anti-arrhythmic drugs, compared to traditional approaches that employ non-cardiac cells and non-human preclinical animal models of atrial fibrillation.

    The white paper covers:

    • The creation & characterisation of human iPSC-derived atrial cardiomyocytes
    • The validation of human iPSC-derived atrial cardiomyocyte genotype and phenotype
    • The advantages of utilizing human iPSC-derived atrial cardiomyocytes for cardiac research
    Improving biological tools for disease modelling and drug discovery with human iPSC-derived Atrial Cardiomyocytes

    Simply fill out the form to receive your copy!


    Share this post:

    iPSC-derived atrial cardiomyocytes: a reproducible platform for translational disease insights

    Guest Post: Astrocytes in Rett Syndrome: why we shouldn’t ignore them?